These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
610 related articles for article (PubMed ID: 31655197)
1. Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas. Cheng N; Liu Y; Zhao G; Xu Y; Zhang T; Chen Y; Yan G; Hu Y; Yao S; Wang Z; Wang C; Chen Z; Hu Z; Liu D; Chen T Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):340-348. PubMed ID: 31655197 [TBL] [Abstract][Full Text] [Related]
2. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169 [TBL] [Abstract][Full Text] [Related]
3. [The efficacy and safety of high dose versus standard dose radiotherapy in concurrent chemoradiotherapy for patients with esophageal squamous cell carcinoma]. Ren XJ; Wang L; Han C; Liu LL Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):135-139. PubMed ID: 30862144 [No Abstract] [Full Text] [Related]
4. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial. Wang L; Liu L; Cao Y; Chen X; Liu S; Li X; Han J; Wang Q; Han C BMC Cancer; 2024 Jun; 24(1):679. PubMed ID: 38831450 [TBL] [Abstract][Full Text] [Related]
5. A phase I study of concurrent weekly carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer patients with positive pelvic lymph nodes. Mabuchi S; Takahashi R; Isohashi F; Yokoi T; Ito K; Tsutui T; Ogata T; Yoshioka Y; Ogawa K; Kimura T Int J Gynecol Cancer; 2013 Sep; 23(7):1279-86. PubMed ID: 23835505 [TBL] [Abstract][Full Text] [Related]
6. A Phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancer: WJTOG 3305. Tada T; Chiba Y; Tsujino K; Fukuda H; Nishimura Y; Kokubo M; Negoro S; Kudoh S; Fukuoka M; Nakagawa K; Nakanishi Y Int J Radiat Oncol Biol Phys; 2012 May; 83(1):327-31. PubMed ID: 22079726 [TBL] [Abstract][Full Text] [Related]
7. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study. Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394 [TBL] [Abstract][Full Text] [Related]
8. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342 [TBL] [Abstract][Full Text] [Related]
9. Phase I study of concurrent selective lymph node late-course accelerated hyperfractionated radiotherapy and S-1 plus cisplatin for locally advanced oesophageal squamous cell carcinoma. Li M; Fu C; Zhang W; Huang W; Wang Z; Zhou T; Lin H; Li B Br J Radiol; 2016; 89(1060):20150476. PubMed ID: 26891913 [TBL] [Abstract][Full Text] [Related]
10. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. Gao LR; Wang X; Han W; Deng W; Li C; Wang X; Zhao Y; Ni W; Chang X; Zhou Z; Deng L; Wang W; Liu W; Liang J; Zhang T; Bi N; Wang J; Zhai Y; Feng Q; Lv J; Li L; Xiao Z BMC Cancer; 2020 Sep; 20(1):901. PubMed ID: 32962674 [TBL] [Abstract][Full Text] [Related]
11. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271 [TBL] [Abstract][Full Text] [Related]
12. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. Chen D; Menon H; Verma V; Seyedin SN; Ajani JA; Hofstetter WL; Nguyen QN; Chang JY; Gomez DR; Amini A; Swisher SG; Blum MA; Younes AI; Barsoumian HB; Erasmus JJ; Lee JH; Bhutani MS; Hess KR; Minsky BD; Welsh JW JAMA Oncol; 2019 Nov; 5(11):1597-1604. PubMed ID: 31529018 [TBL] [Abstract][Full Text] [Related]
13. Radiation Dose-escalated Chemoradiotherapy Using Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Unresectable Thoracic Oesophageal Squamous Cell Carcinoma: A Single-institution Phase I Study. Sakanaka K; Ishida Y; Fujii K; Ishihara Y; Nakamura M; Hiraoka M; Mizowaki T Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):191-201. PubMed ID: 32768158 [TBL] [Abstract][Full Text] [Related]
14. Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial. Lin Q; Liu YE; Ren XC; Wang N; Chen XJ; Wang DY; Zong J; Peng Y; Guo ZJ; Hu J Radiat Oncol; 2013 Aug; 8(1):201. PubMed ID: 23957889 [TBL] [Abstract][Full Text] [Related]
15. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study. Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289 [TBL] [Abstract][Full Text] [Related]
16. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546 [TBL] [Abstract][Full Text] [Related]
17. A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. Li C; Ni W; Wang X; Zhou Z; Deng W; Chang X; Chen D; Feng Q; Liang J; Wang X; Deng L; Wang W; Bi N; Zhang T; Xiao Z Radiat Oncol; 2019 Mar; 14(1):48. PubMed ID: 30876442 [TBL] [Abstract][Full Text] [Related]
18. A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma. Xia Y; Li YH; Chen Y; Liu Q; Zhang JH; Deng JY; Ai TS; Zhu HT; Badakhshi H; Zhao KL Int J Clin Oncol; 2018 Jun; 23(3):458-465. PubMed ID: 29435872 [TBL] [Abstract][Full Text] [Related]
19. Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy. Kong Y; Su M; Fang J; Chen M; Zheng C; Jiang Y; Tao K; Wang C; Qiu G; Ji Y; Wang Y; Yang Y Sci Rep; 2024 Jul; 14(1):16495. PubMed ID: 39019976 [TBL] [Abstract][Full Text] [Related]
20. Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial. Pöttgen C; Gkika E; Stahl M; Abu Jawad J; Gauler T; Kasper S; Trarbach T; Herrmann K; Lehmann N; Jöckel KH; Lax H; Stuschke M Radiat Oncol; 2021 Mar; 16(1):59. PubMed ID: 33757534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]